


For Immediate Release

International Isotopes, Inc. Announces the Amendment of the Acquisition of the AMICI, Inc. Product Line

IDAHO FALLS, IDAHO, January 9th, 2025.

International Isotopes Inc. (OTCQB: INIS) ("International Isotopes," "INIS" or the "Company") is pleased to announce that it has amended and finalized the Asset Purchase Agreement with AMICI, Inc., dated June 16th, 2023. To make up for a shortfall of inventory and assets INIS was to receive under the original agreement, INIS will receive the manufacturing molds, device registrations, trademarks, and all production rights to the AMICI, Inc. line of Xenon System products as well as the registered intellectual property to Swirler® and Tru-Fit™ Mouthpiece products.



Shahe Bagerdjian, President of INIS, commented, "We're glad to have come to an agreement with Mr. Bono to finalize the Asset Purchase Agreement. It's good to now have full control of the intellectual property behind the Swirler® and Tru-Fit™ and we look forward to the Xenon System joining the rest of our RadVent medical device lineup in 2025."

AMICI, Inc. had been a leading manufacturer and distributor of diagnostic and therapeutic products for lung ventilation, including masks, mouthpieces, bacteria/virus filters, absorbents, and the revolutionary Swirler® Radioaerosol System. This acquisition will further complement the Company's Medical Device segment and will be marketed under our RadVent product line.

For more information about the RadVent Swirler®, Tru-Fit™, and Xenon Systems, please visit radvent.com.

About International Isotopes Inc.

International Isotopes Inc. (INIS), established in 1995, with its headquarters in Idaho Falls, ID, USA, manufactures a wide range of radioisotope-focused products. INIS manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer. INIS manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems as well as industrial calibration standards under its RadQual brand. The Company also manufactures Cobalt-60 sealed source products and provides contract manufacturing of various drug products as well as radioisotope API supply for 3rd party theranostics clients. INIS recently launched a manufacturing joint venture with Alpha Nuclides, to bring INIS and RadQual products into China via Radnostix China. The Company is working to launch its RadVent brand of medical devices in 2025, which includes the Swirler® and Tru-Fit™ product lines.

For more information, visit intisoid.com.

International Isotopes Inc. Safe Harbor Statement

Certain statements in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements with respect to the Company’s future growth expectations. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance, or achievements of International Isotopes Inc. to be materially different from any future results, performance or achievements of the Company expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in the Company’s filings with the Securities and Exchange Commission at www.sec.gov, including its Annual Report on Form 10-K for the year ended December 31, 2023. Investors, potential investors, and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and International Isotopes, Inc. and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Investor Relations Contact:

David Drewitz
Creative Options Communications
Investor and Public Relations
david@creativeoptionscommunications.com
www.creativeoptionsmarketing.com
972.814.5723

International Isotopes Contact:

info@intisoid.com
intisoid.com
208.524.5300